Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pediatric long-term roll-over study of Tafinlar and/or Mekinist
2023-509276-42-00Phase 4Authorised
- Sponsor
- Novartis
- Start
- Oct 2019
- Modality
- Small Molecules
- Countries
- 19
01
Overview
Phase 4, open-label trial of dabrafenib + trametinib and trametinib in cancer (3 arms), sponsored by Novartis. Primary endpoint: Safety and tolerability. Planned start Oct 2019; status: authorised.
02
Drugs
dabrafenib + trametinibtrametinib
03
Conditions
cancer
Beyond the preview
Go deeper on 2023-509276-42-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509276-42-00.